Evidence Intelligence™
- EvidenceScore™
- 76
- Strong
- ImpactScore™
- 74
- Positive
- ConsistencyScore™
- 100
- consistent
Estudios de apoyo: Basado en 4 estudios
Add to Evidence TrackerResumen de Investigación
Analyzed using Evidence Intelligence™
Dulaglutide improves HbA1c more than insulin glargine in T2D
Última actualización 12 de septiembre de 2026
Key finding
HbA1c decreased by 18.9 mmol/mol (1.73%)
This study compared once-weekly dulaglutide with daily insulin glargine in Asian patients with type 2 diabetes, finding dulaglutide resulted in greater HbA1c reductions.
Quick read
Study at a glance
The essential study design details in one scan.
EvidenceScore™
Moderate
Study type
RCTs
Follow-up
Long-Term (1–5 y)
Risk of bias
Some Concerns
Guarda investigacion, organiza estudios y vuelve a encontrar evidencia importante rapidamente.
Plain-language summary
What this paper says
A plain-language read of the study’s main message and where it applies.
Study focus
This study compared once-weekly dulaglutide with daily insulin glargine in Asian patients with type 2 diabetes, finding dulaglutide resulted in greater HbA1c reductions.
Clinical relevance
These findings are significant for clinicians treating Asian patients with type 2 diabetes, as they suggest that dulaglutide may offer a more effective and safer alternative to insulin glargine. Improved HbA1c levels can lead to better long-term health outcomes, and the reduction in weight gain and hypoglycemic events enhances the overall treatment experience for patients.
Keep in mind
The study's population was limited to Asian patients, affecting generalizability. Sample sizes for each treatment group were not specified. Long-term effects beyond 26 weeks were not assessed.
Published in
Referencia de la Revista
Publication details and source links for this paper.
Weiqing W, Luis N, Ekaterina F, et al. Once-Weekly Dulaglutide Provides Greater Improvement in HbA1c Compared to Insulin Glargine in Asian Patients with Type 2 Diabetes. Diabetes, Obesity & Metabolism. 2018;21(2):234-243. doi:10.1111/dom.13506
Efectos Principales
Dulaglutide 1.5 mg reduced HbA1c by 18.9 mmol/mol (1.73%) at week 26.
Dulaglutide 0.75 mg reduced HbA1c by 14.5 mmol/mol (1.33%) at week 26.
More patients achieved HbA1c <53.0 mmol/mol with dulaglutide 1.5 mg compared to glargine (P < 0.001).
Evidence network
How this study fits
Understand where this research contributes within the broader evidence network.
Evidence Context
This study contributes evidence to Dulaglutide, Insulin glargine once daily and Body weight, Gastrointestinal disorders incidence, HbA1c, and 2 more.
This study contributes evidence to
Primary intervention
Dulaglutide
Primary outcomes
- Body weight
- Gastrointestinal disorders incidence
- HbA1c
Evidence topics
Primary intervention
Primary outcomes
Evidence relationships
Intervention and outcome relationships this study adds to the evidence network.
8
Evidence pairs
8
Relationships
3
Evidence topics
contributes_evidence
Editorial context
Why this study matters
See why this paper is useful beyond its individual results.
Evidence network role
This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.
Moderate contributionModerate confidenceNetwork score: 68
3
Related topics
8
Evidence pairs
1079
Related studies
High relevance in at least one topic
Why it is useful
- Contributes to 8 evidence relationships
- Includes primary outcome data
- Linked to 3 direct semantic evidence topics
Topic contributions
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Agrega evidencia relacionada a tu Evidence Tracker
Guarda estudios y paginas de evidencia, organiza tu Evidence Tracker y manten en un solo lugar la investigacion que te importa.
Evidencia principal
Relación de evidencia
GLP-1 Receptor Agonists and HbA1c
Evidencia relacionada
Relación de evidencia
GLP-1 Receptor Agonists and Body Weight
Guardar evidencia
Relación de evidencia
GLP-1 Receptor Agonists and Gastrointestinal Adverse Events
Guardar evidencia
Core evidence
Study findings
The primary outcomes reported in this study.
Gastrointestinal disorders incidence
Dulaglutide → Gastrointestinal disorders incidence
Dulaglutide → Gastrointestinal disorders incidence
Evidence Intelligence™
- EvidenceScore™
- 76
- Strong
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- 100
- consistent
Estudios de apoyo: Basado en 4 estudios
Add to Evidence TrackerEvidence Intelligence™
- EvidenceScore™
- 84
- Strong
- ImpactScore™
- 90
- Very Positive
- ConsistencyScore™
- 80
- consistent
Estudios de apoyo: Basado en 5 estudios
Add to Evidence TrackerIncidence of hypoglycaemia
Dulaglutide → Incidence of hypoglycaemia
Dulaglutide → Incidence of hypoglycaemia
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Estudios de apoyo: Basado en 1 estudio
Add to Evidence TrackerPercentage of patients with HbA1c < 7%
Dulaglutide → Percentage of patients with HbA1c < 7%
Dulaglutide → Percentage of patients with HbA1c < 7%
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Estudios de apoyo: Basado en 1 estudio
Add to Evidence TrackerEvidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- unclear
- Not enough independent studies
Estudios de apoyo: Basado en 1 estudio
Add to Evidence TrackerEvidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Estudios de apoyo: Basado en 1 estudio
Add to Evidence TrackerIncidence of hypoglycaemia
Insulin glargine once daily → Incidence of hypoglycaemia
Insulin glargine once daily → Incidence of hypoglycaemia
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 25
- Negative
- ConsistencyScore™
- unclear
- Not enough independent studies
Estudios de apoyo: Basado en 1 estudio
Add to Evidence TrackerEvidence Library
Build your evidence library
Save research, organize studies, and quickly find important evidence again.
La Evidencia Sugiere
- Dulaglutide 1.5 mg showed a significant HbA1c reduction of 18.9 mmol/mol.
- More patients on dulaglutide achieved HbA1c targets compared to insulin glargine.
- Dulaglutide was associated with weight loss and lower hypoglycemia rates.
A quién se aplica
- Asian patients aged 18 and older with type 2 diabetes.
- Patients seeking alternatives to daily insulin therapy.
Tener en Cuenta
- Results may not apply to non-Asian populations.
- The study duration was limited to 26 weeks.
- Further research is needed to evaluate long-term safety and efficacy.
Entre Líneas
- The study's population was limited to Asian patients, affecting generalizability.
- Sample sizes for each treatment group were not specified.
- Long-term effects beyond 26 weeks were not assessed.
Evidence Library
Build your evidence library
Save research, organize studies, and quickly find important evidence again.
Connected Evidence
Explore related studies, evidence collections, and research questions.
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
This study contributes to evidence on GLP-1 Receptor Agonists and HbA1c, GLP-1 Receptor Agonists and Body Weight.
Relaciones de evidencia relacionadas
Explore in Evidence ExplorerThis study contributes to the evidence on the following intervention-outcome relationships.
Medications
GLP-1 Receptor Agonists → HbA1c
Medications
Evidence Intelligence™
- EvidenceScore™
- 84
- Strong
- ImpactScore™
- 90
- Very Positive
- ConsistencyScore™
- 80
- consistent
Estudios de apoyo: Basado en 5 estudios
View evidenceMedications
GLP-1 Receptor Agonists → Body Weight
Medications
Evidence Intelligence™
- EvidenceScore™
- 76
- Strong
- ImpactScore™
- 74
- Positive
- ConsistencyScore™
- 100
- consistent
Estudios de apoyo: Basado en 4 estudios
View evidenceIncluido en estas colecciones de evidencia
Curated evidence collections and hubs this study is part of.
GLP-1 Receptor Agonists Evidence Hub
All studies on GLP-1 Receptor Agonists
5 studies
intervention_hubContributes to GLP-1 Receptor Agonists evidence base.
HbA1c Evidence Hub
All studies measuring HbA1c
5 studies
outcome_hubMeasures HbA1c as a key outcome.
Body Weight Evidence Hub
All studies measuring Body Weight
4 studies
outcome_hubMeasures Body Weight as a key outcome.
Explora más en Evidence Explorer
Jump to pre-filtered views in Evidence Explorer.
All studies on Dulaglutide and HbA1c
Intervention: DulaglutideOutcome: HbA1c
5 results
All studies on Dulaglutide and Body weight
Intervention: DulaglutideOutcome: Body weight
4 results
All studies on Dulaglutide
Intervention: Dulaglutide
5 results
All studies measuring HbA1c
Outcome: HbA1c
5 results
All studies measuring Body weight
Outcome: Body weight
4 results
Questions answered by this study
Generated from the study's connected evidence using Evidence Intelligence™.
Do GLP-1 Receptor Agonists lower HbA1c?
Strong Evidence
GLP-1 Receptor Agonists appear to lower HbA1c.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
- 1
HbA1c
EvidenceScore™ Strong | EvidenceScore™ 83.5 | strong positive | ConsistencyScore™ Consistent | 1 study
Why this answer: This answer is based on 45 supporting studies with consistent results and a positive effect signal.
Do GLP-1 Receptor Agonists affect body weight?
Strong Evidence
GLP-1 Receptor Agonists may affect body weight.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
- 1
Body weight
EvidenceScore™ Strong | EvidenceScore™ 76.1 | moderate positive | ConsistencyScore™ Consistent | 1 study
Why this answer: This answer is based on 43 supporting studies with consistent results and a positive effect signal.
Do GLP-1 Receptor Agonists affect gastrointestinal adverse events?
Strong Evidence
Current evidence does not show a clear effect of GLP-1 Receptor Agonists on gastrointestinal adverse events.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
- 1
Gastrointestinal disorders incidence
EvidenceScore™ Strong | EvidenceScore™ 76.1 | neutral | ConsistencyScore™ Consistent | 1 study
Why this answer: This answer is based on 12 supporting studies and existing graph evidence signals.
Do GLP-1 Receptor Agonists affect hypoglycemia?
Strong Evidence
GLP-1 Receptor Agonists may affect hypoglycemia.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
- 1
Incidence of hypoglycaemia
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on 14 supporting studies with consistent results and a positive effect signal.
Next steps
Continue your research
Choose a next path through related evidence topics, Evidence Explorer views, and research summaries.
Evidence topics
Follow the topics this study contributes to.
Explore in Evidence Explorer
Open broader Evidence Explorer views for this relationship.
Related research
Read related research summaries.
Switching to tirzepatide improves glycemic control and weight in type 2 diabetesCombination Therapy Reduces HbA1c and Weight in Type 2 DiabetesDietary interventions improve glycemic control in pre-diabetic patientsInsulin glargine plus metformin and glimepiride improves glycemic control in type 2 diabetes.Dulaglutide may improve weight loss in obese patients with diabetes
Sin anuncios. Sin rastreo.
Centrada en la evidencia, no en la publicidad.
Segura y privada
Tus datos siempre están protegidos.
Siempre al día
Se agregan nuevos estudios todos los días.